HomePBDA • FRA
add
Protalix Biotherapeutics Inc
Previous close
€1.46
Day range
€1.46 - €1.51
Year range
€0.64 - €2.70
Market cap
132.94M USD
Avg Volume
322.00
P/E ratio
-
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 10.11M | 169.82% |
Operating expense | 6.08M | 1.27% |
Net income | -3.62M | 21.24% |
Net profit margin | -35.79 | 70.81% |
Earnings per share | — | — |
EBITDA | -3.80M | 16.21% |
Effective tax rate | 3.03% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 34.74M | -28.35% |
Total assets | 73.89M | -17.74% |
Total liabilities | 28.68M | -52.22% |
Total equity | 45.21M | — |
Shares outstanding | 79.61M | — |
Price to book | 2.52 | — |
Return on assets | -14.07% | — |
Return on capital | -20.90% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -3.62M | 21.24% |
Cash from operations | -5.06M | -220.77% |
Cash from investing | -312.00K | 48.51% |
Cash from financing | 5.08M | — |
Net change in cash | -302.00K | -108.45% |
Free cash flow | -3.76M | -175.74% |
About
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease. Wikipedia
CEO
Founded
1993
Headquarters
Website
Employees
213
